<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//TaxonX//DTD Taxonomic Treatment Publishing DTD v0 20100105//EN" "https://skindeep.skinonline.org/nlm/tax-treatment-NS0.dtd">
<article xmlns:tp="http://www.plazi.org/taxpub" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="en">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">133</journal-id>
      <journal-id journal-id-type="index">urn:lsid:arphahub.com:pub:3743a65a-6869-528e-a7d9-aa502935b7f6</journal-id>
      <journal-title-group>
        <journal-title xml:lang="en">SKINdeep</journal-title>
        <abbrev-journal-title xml:lang="en">skinonline</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="ppub">3061-029X</issn>
      <issn pub-type="epub">3061-0281</issn>
      <publisher>
        <publisher-name>Austrian Academy of Sciences Press</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="doi">10.1553/skindeep.2026.200237</article-id>
      <article-id pub-id-type="publisher-id">200237</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Perspectives</subject>
        </subj-group>
        <subj-group subj-group-type="scientific_subject">
          <subject>Lymphoma</subject>
          <subject>Malignant</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Feeding the fire: How inflammation may sustain mycosis fungoides and Sézary syndrome – and options to disrupt</article-title>
      </title-group>
      <contrib-group content-type="authors">
        <contrib contrib-type="author" corresp="yes">
          <name name-style="western">
            <surname>Schratter</surname>
            <given-names>Hanna</given-names>
          </name>
          <email xlink:type="simple">hanna.schratter@medunigraz.at</email>
          <uri content-type="orcid">https://orcid.org/0009-0005-8081-8228</uri>
          <xref ref-type="aff" rid="A1">1</xref>
          <role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
          <role content-type="http://credit.niso.org/contributor-roles/writing-original-draft/">Writing - original draft</role>
          <role content-type="http://credit.niso.org/contributor-roles/investigation/">Investigation</role>
          <role content-type="http://credit.niso.org/contributor-roles/visualization/">Visualization</role>
        </contrib>
        <contrib contrib-type="author" corresp="no">
          <name name-style="western">
            <surname>Woltsche</surname>
            <given-names>Johannes</given-names>
          </name>
          <uri content-type="orcid">https://orcid.org/0000-0002-2240-6736</uri>
          <xref ref-type="aff" rid="A1">1</xref>
          <role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing - review and editing</role>
        </contrib>
        <contrib contrib-type="author" corresp="no">
          <name name-style="western">
            <surname>Fink-Puches</surname>
            <given-names>Regina</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
          <role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
          <role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing - review and editing</role>
          <role content-type="http://credit.niso.org/contributor-roles/supervision/">Supervision</role>
        </contrib>
      </contrib-group>
      <aff id="A1">
        <label>1</label>
        <addr-line content-type="verbatim">Department of Dermatology and Venereology, Medical University of Graz, Graz, Austria</addr-line>
        <institution>Department of Dermatology and Venereology, Medical University of Graz</institution>
        <addr-line content-type="city">Graz</addr-line>
        <country>Austria</country>
        <uri content-type="ror">https://ror.org/02n0bts35</uri>
      </aff>
      <author-notes>
        <fn fn-type="corresp">
          <p>Corresponding author: Hanna Schratter (<email xlink:type="simple">hanna.schratter@medunigraz.at</email>)</p>
        </fn>
        <fn>
          <p>Subject editor: Georg Stingl</p>
        </fn>
      </author-notes>
      <pub-date pub-type="collection">
        <year>2026</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>15</day>
        <month>10</month>
        <year>2026</year>
      </pub-date>
      <volume>2</volume>
      <elocation-id>e200237</elocation-id>
      <uri content-type="arpha" xlink:href="http://openbiodiv.net/F58C49FF-43FD-59D7-941A-8D63548BF3F8">F58C49FF-43FD-59D7-941A-8D63548BF3F8</uri>
      <history>
        <date date-type="received">
          <day>19</day>
          <month>05</month>
          <year>2026</year>
        </date>
        <date date-type="accepted">
          <day>24</day>
          <month>08</month>
          <year>2026</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Hanna Schratter, Johannes Woltsche, Regina Fink-Puches</copyright-statement>
        <license license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/" xlink:type="simple">
          <license-p>This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY-NC 4.0), which permits to copy and distribute the article for non-commercial purposes, provided that the article is not altered or modified and the original author and source are credited.</license-p>
        </license>
      </permissions>
      <abstract>
        <label>Abstract</label>
        <p>Cutaneous T-cell lymphomas (<abbrev xlink:title="Cutaneous T-cell lymphomas">CTCL</abbrev>), including mycosis fungoides (<abbrev xlink:title="Sézary syndrome">MF</abbrev>) and Sézary syndrome (<abbrev xlink:title="Sézary syndrome">SS</abbrev>), are histopathologically characterized by a prominent inflammatory infiltrate, accompanying the malignant cells in the skin. This infiltrate contributes to diagnostic uncertainty and appears to support the persistence of malignant T cells. Growing evidence supports an inflammation-driven disease model, in which cytokine networks, microbial triggers, and direct cellular interactions shape a tumor-permissive microenvironment. In this perspective, we discuss how established skin-directed therapies achieve clinical benefits not only by directly affecting malignant cells, but also by remodeling the lesional immune milieu and reducing supportive inflammatory infiltrates. We also highlight the importance of targeting microenvironmental signaling pathways, focusing on the OX40/OX40L costimulatory axis and JAK/STAT pathway dysregulation as therapeutic targets. Overall, we propose that integrating tumor-directed therapy with approaches that modify the inflammatory niche may offer a rational strategy to improve long-term disease control in <abbrev xlink:title="Sézary syndrome">MF</abbrev>/<abbrev xlink:title="Sézary syndrome">SS</abbrev>.</p>
      </abstract>
      <kwd-group>
        <label>Key words:</label>
        <kwd>Cutaneous T-cell lymphoma</kwd>
        <kwd>Mycosis fungoides</kwd>
        <kwd>Sézary syndrome</kwd>
        <kwd>inflammatory infiltrate</kwd>
        <kwd>tumor microenvironment</kwd>
      </kwd-group>
    </article-meta>
    <notes>
      <sec sec-type="Citation" id="sec1">
        <title>Citation</title>
        <p>Schratter H, Woltsche J, Fink-Puches R (2026) Feeding the fire: How inflammation may sustain mycosis fungoides and Sézary syndrome – and options to disrupt. SKINdeep 2: e200237. <ext-link xlink:href="10.1553/skindeep.2026.200237" ext-link-type="doi">https://doi.org/10.1553/skindeep.2026.200237</ext-link></p>
      </sec>
    </notes>
  </front>
  <body>
    <sec sec-type="1.0 Introduction" id="sec2">
      <title>1.0 Introduction</title>
      <p>Cutaneous T-cell lymphomas (<abbrev xlink:title="Cutaneous T-cell lymphomas">CTCL</abbrev>) are a heterogeneous group of extranodal non-Hodgkin lymphomas that arise in the skin and often share clinical similarities with common inflammatory dermatoses such as eczema, psoriasis, or chronic dermatitis in their early presentation [<xref ref-type="bibr" rid="B1">1</xref>–<xref ref-type="bibr" rid="B3">3</xref>]. Histopathologically, lesions are characterized not only by the presence of malignant T cells, but also by a significant inflammatory infiltrate of benign lymphocytes and other immune cells. This infiltrate contributes to the diagnostic challenge and reflects the underlying inflammatory microenvironment [<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B4">4</xref>, <xref ref-type="bibr" rid="B5">5</xref>].</p>
      <p>This perspective article aims to discuss how established skin-directed and immunomodulatory therapies, including phototherapy, topical corticosteroids, interferons, retinoids, and radiotherapy, may modulate the inflammatory tumor microenvironment by reducing microenvironmental signals that support the persistence and survival of malignant T cells, while potentially restoring a more effective anti-tumor immune balance. Building on this concept, we explore emerging therapeutic strategies, such as JAK (Janus kinase) inhibitors, OX40/OX40L pathway blockade and other immunomodulators, which may target the same pathogenic mechanisms more selectively and effectively.</p>
      <sec sec-type="1.1 The role of inflammation in driving tumor progression in MF/SS and its potential inhibition" id="sec3">
        <title>1.1 The role of inflammation in driving tumor progression in <abbrev xlink:title="Sézary syndrome">MF</abbrev>/<abbrev xlink:title="Sézary syndrome">SS</abbrev> and its potential inhibition</title>
        <p>Mycosis fungoides and Sézary syndrome are diseases in which chronic inflammation contributes to tumor progression. The proliferation and survival of malignant T cells are significantly influenced by their interactions with the surrounding microenvironment. Krejsgaard et al. described this relationship as “malignant inflammation”, characterized by a complex interplay of cytokine signaling and cellular interactions that create a pro-tumorigenic inflammatory environment [<xref ref-type="bibr" rid="B6">6</xref>]. In the early stages of mycosis fungoides, the cutaneous infiltrate is dominated by reactive CD8<sup>+</sup> cytotoxic T cells and Th1-polarized CD4<sup>+</sup> T cells, which may contribute to tumor immune surveillance. However, as the disease progresses, the immune landscape gradually shifts towards a Th2-dominant and immunosuppressive phenotype [<xref ref-type="bibr" rid="B2">2</xref>–<xref ref-type="bibr" rid="B5">5</xref>, <xref ref-type="bibr" rid="B7">7</xref>, <xref ref-type="bibr" rid="B8">8</xref>]. This immunological shift transforms a protective inflammatory response into a self-sustaining lymphocytic microenvironment, where malignant and benign T cells interact to stimulate disease activity [<xref ref-type="bibr" rid="B4">4</xref>–<xref ref-type="bibr" rid="B6">6</xref>]. Understanding the mechanisms that drive and sustain this process is essential for explaining how current therapies achieve remission by modulating the lesional immune milieu, as well as for developing future treatment strategies [<xref ref-type="bibr" rid="B9">9</xref>–<xref ref-type="bibr" rid="B12">12</xref>].</p>
      </sec>
    </sec>
    <sec sec-type="2.0 Skin-directed therapies" id="sec4">
      <title>2.0 Skin-directed therapies</title>
      <p>Current therapeutic strategies for <abbrev xlink:title="Sézary syndrome">MF</abbrev>/<abbrev xlink:title="Sézary syndrome">SS</abbrev> are primarily directed at controlling the malignant T-cell clone and improving clinical symptoms. Increasing evidence suggests that several established therapies, particularly skin-directed treatments, may additionally exert therapeutic effects by reshaping the inflammatory tumor microenvironment.</p>
      <p>Phototherapy and topical corticosteroids are widely used as first-line treatments for early-stage disease, achieving clinical benefit through immunomodulatory mechanisms. These therapies highlight the importance of targeting the inflammatory milieu that supports the survival of malignant T cells.</p>
      <sec sec-type="2.1 Corticosteroids" id="sec5">
        <title>2.1 Corticosteroids</title>
        <p>Topical corticosteroids are widely used as first-line skin-directed therapy for early-stage mycosis fungoides, as recommended by international consensus guidelines [<xref ref-type="bibr" rid="B13">13</xref>]. However, data specifically addressing their molecular effects in <abbrev xlink:title="Sézary syndrome">MF</abbrev> are limited, and the mechanisms described below are largely inferred from their established immunomodulatory actions in other inflammatory settings.</p>
        <p>Mechanistically, glucocorticoids are known to exert broad immunomodulatory effects through binding to cytoplasmic glucocorticoid receptors, which translocate to the nucleus and regulate inflammatory gene expression predominantly through transrepression of key transcription factors such as NF-κB and AP-1, while also inducing anti-inflammatory mediators including annexin A1 (lipocortin-1) and IL-10, thereby inhibiting phospholipase A2, cyclooxygenase-2 and inducible nitric oxide synthase and reducing the production of pro-inflammatory cytokines [<xref ref-type="bibr" rid="B14">14</xref>–<xref ref-type="bibr" rid="B16">16</xref>].</p>
        <p>In addition, glucocorticoids promote apoptosis of T lymphocytes and other inflammatory cells and impair leukocyte recruitment by downregulating endothelial adhesion molecules such as ICAM-1 and E-selectin, while their vasoconstrictive and antimitotic effects further contribute to the resolution of cutaneous inflammation [<xref ref-type="bibr" rid="B14">14</xref>–<xref ref-type="bibr" rid="B17">17</xref>]. In early-stage <abbrev xlink:title="Sézary syndrome">MF</abbrev>, clinical series and retrospective analyses have demonstrated substantial activity of potent topical corticosteroids as monotherapy. In a prospective cohort of patch- and early plaque-stage <abbrev xlink:title="Sézary syndrome">MF</abbrev>, high response rates and complete remissions were observed with class I steroids, establishing their effectiveness in skin-limited disease [<xref ref-type="bibr" rid="B18">18</xref>, <xref ref-type="bibr" rid="B19">19</xref>].</p>
        <p>More recently, Kartan et al. reported in a retrospective analysis that topical corticosteroid monotherapy was associated with reductions in body surface area and <abbrev xlink:title="Modified Severity-Weighted Assessment Tool">mSWAT</abbrev> (Modified Severity-Weighted Assessment Tool) scores in early-stage <abbrev xlink:title="Sézary syndrome">MF</abbrev>, with complete responses observed in a subset of patients [<xref ref-type="bibr" rid="B20">20</xref>].</p>
        <p>Taken together, these mechanisms suggest that topical corticosteroids, beyond symptomatic control, reduce lymphocytic infiltrates in <abbrev xlink:title="Sézary syndrome">MF</abbrev> lesions and may thereby likely diminish the inflammatory support that sustains the malignant microenvironment.</p>
      </sec>
      <sec sec-type="2.2 Phototherapy" id="sec6">
        <title>2.2 Phototherapy</title>
        <p>Phototherapy – most commonly psoralen plus ultraviolet A (<abbrev xlink:title="plus ultraviolet A">PUVA</abbrev>) and narrow-band ultraviolet B (<abbrev xlink:title="narrow-band ultraviolet B">NB-UVB</abbrev>) – is recommended as a first-line skin-directed treatment for early-stage <abbrev xlink:title="Sézary syndrome">MF</abbrev> in international guidelines [<xref ref-type="bibr" rid="B21">21</xref>]. Although both modalities are clinically effective, they differ substantially in their molecular and cellular mechanisms of action. As the effects of <abbrev xlink:title="plus ultraviolet A">PUVA</abbrev> on the tumor microenvironment have been more extensively characterized, the following section focuses primarily on <abbrev xlink:title="plus ultraviolet A">PUVA</abbrev>.</p>
        <p><abbrev xlink:title="plus ultraviolet A">PUVA</abbrev> has been used therapeutically in mycosis fungoides since its first description in <abbrev xlink:title="Sézary syndrome">MF</abbrev> patients by Gilchrest in 1976 [<xref ref-type="bibr" rid="B22">22</xref>] and has since been shown to induce durable remissions, including long-term complete responses in a subset of early-stage patients [<xref ref-type="bibr" rid="B23">23</xref>]. In a randomized clinical trial, low-dose, low-frequency <abbrev xlink:title="plus ultraviolet A">PUVA</abbrev> induced complete remission in approximately 70% of patients with early-stage <abbrev xlink:title="Sézary syndrome">MF</abbrev> and was associated with a marked reduction of lesional lymphocytic infiltrates and malignant T-cell clonality [<xref ref-type="bibr" rid="B24">24</xref>].</p>
        <p>Mechanistically, <abbrev xlink:title="plus ultraviolet A">PUVA</abbrev> exerts both proapoptotic and immunomodulatory effects: UV-induced DNA photoproducts trigger apoptosis of epidermotropic T cells, while broad transcriptional changes in keratinocytes and immune cells reshape the inflammatory milieu of lesional skin [<xref ref-type="bibr" rid="B9">9</xref>].</p>
        <p>Accumulating evidence suggests that phototherapy kills malignant cells directly [<xref ref-type="bibr" rid="B25">25</xref>], and may also disrupt the microenvironmental support on which these cells depend. In <abbrev xlink:title="Sézary syndrome">MF</abbrev> skin, malignant T cells cluster with benign T cells and CCL18 expressing dendritic cells to form „inflammatory synapse networks“; <abbrev xlink:title="plus ultraviolet A">PUVA</abbrev> therapy was shown to dismantle these cell–cell interactions by inducing turnover of benign infiltrating T cells, a change that correlated with clinical improvement [<xref ref-type="bibr" rid="B5">5</xref>]. Remarkably, the infiltrate – which prior to therapy is enriched for Th2-associated chemokines – can shift toward a Th1-skewed profile after <abbrev xlink:title="plus ultraviolet A">PUVA</abbrev>, with increased production of CXCL9, CXCL10 and CXCL11 [<xref ref-type="bibr" rid="B5">5</xref>]. This aligns with earlier findings that <abbrev xlink:title="plus ultraviolet A">PUVA</abbrev> promotes a Th2 to Th1 immune rebalancing in lesions, potentially restoring antitumor immune function [<xref ref-type="bibr" rid="B7">7</xref>]. Phototherapy has been shown to reduce the expression of IL-9 and STAT3/STAT5 in mycosis fungoides lesions. These pathways are involved in the survival of malignant T cells [<xref ref-type="bibr" rid="B26">26</xref>]. In addition, gene expression profiling and immunohistochemical analyses have shown that mycosis fungoides lesions exhibit a baseline deficiency in epidermal type I interferon production, which is restored by <abbrev xlink:title="plus ultraviolet A">PUVA</abbrev> therapy [<xref ref-type="bibr" rid="B27">27</xref>].</p>
        <p>Together, these observations support the concept that both, the direct effects of phototherapy on malignant T cells and its ability to reduce and reprogram the inflammatory infiltrate contribute to the therapeutic response observed with phototherapy, consistent with the broader model of “malignant inflammation”.</p>
      </sec>
      <sec sec-type="2.3 Radiotherapy" id="sec7">
        <title>2.3 Radiotherapy</title>
        <p>Radiotherapy represents an established treatment modality for cutaneous T-cell lymphoma, particularly for localized lesions and, in selected patients with more extensive disease, total skin electron beam therapy (TSEBT). Given the high radiosensitivity of lymphocytes, even low doses of radiation can achieve effective local disease control with acceptable toxicity profiles [<xref ref-type="bibr" rid="B28">28</xref>, <xref ref-type="bibr" rid="B29">29</xref>]. Electron beam therapy is widely used in <abbrev xlink:title="Sézary syndrome">MF</abbrev>/<abbrev xlink:title="Sézary syndrome">SS</abbrev> because electrons provide a favorable dose distribution for cutaneous disease, delivering the highest dose within the target tissue while minimizing radiation exposure of deeper structures. Photon-based approaches (e.g., X-rays) may be considered when greater penetration or specific anatomical coverage is required [<xref ref-type="bibr" rid="B28">28</xref>, <xref ref-type="bibr" rid="B29">29</xref>].</p>
        <p>Radiotherapy induces DNA damage, including DNA double-strand breaks, which can lead to micronuclei formation and cytosolic DNA accumulation. In other cancer models, these processes have been shown to activate the cGAS–STING pathway, resulting in type I interferon production and enhanced anti-tumor immune responses [<xref ref-type="bibr" rid="B30">30</xref>–<xref ref-type="bibr" rid="B32">32</xref>].</p>
        <p>However, whether these immunostimulatory mechanisms contribute to therapeutic responses in <abbrev xlink:title="Sézary syndrome">MF</abbrev>/<abbrev xlink:title="Sézary syndrome">SS</abbrev> remains unclear.</p>
        <p>Beyond direct cytotoxic effects, low-dose radiotherapy has been reported in other tumor entities (highly metastatic lung adenocarcinoma tumors) to exert immunomodulatory effects, including macrophage polarization, modulation of immune cell trafficking, and enhancement of immune effector functions [<xref ref-type="bibr" rid="B33">33</xref>]. The extent to which these mechanisms apply to <abbrev xlink:title="Sézary syndrome">MF</abbrev>/<abbrev xlink:title="Sézary syndrome">SS</abbrev> requires further investigation. In addition, radiotherapy may reduce the inflammatory infiltrate within lesions, potentially disrupting microenvironmental signals that support malignant T-cell persistence.</p>
        <p>Together, these observations provide a rationale for investigating the potential role of radiotherapy-induced tumor microenvironment modulation in <abbrev xlink:title="Sézary syndrome">MF</abbrev>/<abbrev xlink:title="Sézary syndrome">SS</abbrev>, although direct evidence for such effects remains limited.</p>
      </sec>
    </sec>
    <sec sec-type="3.0 Interferon" id="sec8">
      <title>3.0 Interferon</title>
      <p>Interferon-α is an established systemic treatment for <abbrev xlink:title="Sézary syndrome">MF</abbrev>/<abbrev xlink:title="Sézary syndrome">SS</abbrev> and is included in current treatment guidelines. As interferon-α represents one of the most frequently used combination partners for <abbrev xlink:title="plus ultraviolet A">PUVA</abbrev> in <abbrev xlink:title="Sézary syndrome">MF</abbrev>, its impact on the tumor microenvironment deserves particular attention. Its immunomodulatory effects include activation of CD8<sup>+</sup> T cells and NK cells, upregulation of MHC class I expression on malignant lymphocytes, and attenuation of the Th2-skewed immune milieu [<xref ref-type="bibr" rid="B34">34</xref>].</p>
      <p>In addition, Furudate et al. demonstrated that IFN-α modulates tumor-associated macrophages by reducing the production of CCL17 and CCL18 while increasing the Th1-associated chemokines CXCL10 and CXCL11, suggesting a shift toward a more antitumor immune microenvironment [<xref ref-type="bibr" rid="B35">35</xref>].</p>
    </sec>
    <sec sec-type="4.0 Retinoids" id="sec9">
      <title>4.0 Retinoids</title>
      <p>Besides interferon-α, retinoids – particularly bexarotene – represent another well-established combination partner for <abbrev xlink:title="plus ultraviolet A">PUVA</abbrev> in the treatment of <abbrev xlink:title="Sézary syndrome">MF</abbrev>. Bexarotene is a third-generation, retinoid X receptor (RXR)-selective retinoid approved for the treatment of both early- and advanced-stage <abbrev xlink:title="Cutaneous T-cell lymphomas">CTCL</abbrev>. While the clinical efficacy of this combination has long been recognized, recent evidence suggests that part of its therapeutic benefit may also be mediated through modulation of the tumor microenvironment.</p>
      <p>Tanita et al. demonstrated that bexarotene suppresses the production of CCL22 by M2-polarized tumor-associated macrophages, thereby reducing the recruitment of CCR4<sup>+</sup> malignant T cells, regulatory T cells, and Th2 cells to lesional skin. These findings indicate that, beyond its direct effects on malignant T cells, bexarotene may contribute to a less immunosuppressive and more antitumor immune microenvironment [<xref ref-type="bibr" rid="B36">36</xref>].</p>
    </sec>
    <sec sec-type="5.0 Local and systemic chemotherapy" id="sec10">
      <title>5.0 Local and systemic chemotherapy</title>
      <p>Topical and systemic chemotherapeutic approaches have long been part of the therapeutic armamentarium for cutaneous T-cell lymphoma, although their role differs substantially according to disease stage and treatment setting.</p>
      <p>Chlormethine (2-chloro-N-(2-chloroethyl)-N-methylethan-1-amine, mechlorethamine) is an alkylating agent with potent antiproliferative activity, and its use in mycosis fungoides was first described in 1959 [<xref ref-type="bibr" rid="B37">37</xref>, <xref ref-type="bibr" rid="B38">38</xref>]. As a topical formulation, chlormethine gel is currently recommended as a first-line treatment for early-stage disease (stages IA–IIA) [<xref ref-type="bibr" rid="B13">13</xref>]. Its cytotoxic effects are mediated by DNA alkylation, which induces DNA damage and ultimately leads to cell death [<xref ref-type="bibr" rid="B38">38</xref>, <xref ref-type="bibr" rid="B39">39</xref>]. Notably, contact dermatitis occurs in more than 50% of treated patients [<xref ref-type="bibr" rid="B13">13</xref>]. An association between the development of contact dermatitis and treatment response has been reported, suggesting that this reaction may serve as a clinical predictor of response [<xref ref-type="bibr" rid="B40">40</xref>].</p>
      <p>This may be mechanistically relevant because <abbrev xlink:title="Sézary syndrome">MF</abbrev> lesions are shaped by close interactions among keratinocytes, Langerhans cells, and malignant T cells. Specifically, a chlormethine-induced delayed-type hypersensitivity reaction can shift the local immune milieu from a Th2- toward a Th1-dominated response. This shift promotes the apoptosis of malignant T cells, thereby driving disease regression [<xref ref-type="bibr" rid="B38">38</xref>].</p>
      <p>To contextualize the clinical value of such skin-directed approaches, it is important to note the limitations of systemic alternatives. In fact, systemic chemotherapy, whether administered as a single agent or in combination, has generally shown only limited durability of disease control in <abbrev xlink:title="Sézary syndrome">MF</abbrev>. It is therefore usually reserved for advanced disease or for patients in whom other therapeutic options have been exhausted [<xref ref-type="bibr" rid="B13">13</xref>, <xref ref-type="bibr" rid="B41">41</xref>, <xref ref-type="bibr" rid="B42">42</xref>]. This notable contrast underscores the critical need for effective and durable topical treatments like chlormethine in early-stage disease to delay or avoid the necessity of systemic interventions.</p>
    </sec>
    <sec sec-type="6.0 Antibiotic therapy" id="sec11">
      <title>6.0 Antibiotic therapy</title>
      <p>The rationale for antibiotic therapy in <abbrev xlink:title="Sézary syndrome">MF</abbrev> or <abbrev xlink:title="Sézary syndrome">SS</abbrev> is supported by increasing evidence that <italic><tp:taxon-name><tp:taxon-name-part taxon-name-part-type="genus" reg="Staphylococcus">Staphylococcus</tp:taxon-name-part> <tp:taxon-name-part taxon-name-part-type="species" reg="aureus">aureus</tp:taxon-name-part></tp:taxon-name></italic> colonization contributes to disease progression. Colonization and infection with <italic><tp:taxon-name><tp:taxon-name-part taxon-name-part-type="genus" reg="Staphylococcus">Staphylococcus</tp:taxon-name-part> <tp:taxon-name-part taxon-name-part-type="species" reg="aureus">aureus</tp:taxon-name-part></tp:taxon-name></italic> are common in patients with <abbrev xlink:title="Sézary syndrome">MF</abbrev> or <abbrev xlink:title="Sézary syndrome">SS</abbrev> [<xref ref-type="bibr" rid="B43">43</xref>, <xref ref-type="bibr" rid="B44">44</xref>]. Notably, patients with Sézary syndrome exhibit higher rates of <italic><tp:taxon-name><tp:taxon-name-part taxon-name-part-type="genus" reg="Staphylococcus">S.</tp:taxon-name-part> <tp:taxon-name-part taxon-name-part-type="species" reg="aureus">aureus</tp:taxon-name-part></tp:taxon-name></italic> colonization compared with patients with non-erythrodermic mycosis fungoides [<xref ref-type="bibr" rid="B43">43</xref>].</p>
      <p>For several decades, enterotoxin-producing <italic><tp:taxon-name><tp:taxon-name-part taxon-name-part-type="genus" reg="Staphylococcus">S.</tp:taxon-name-part> <tp:taxon-name-part taxon-name-part-type="species" reg="aureus">aureus</tp:taxon-name-part></tp:taxon-name></italic> has been suspected to play a key role in the pathogenesis [<xref ref-type="bibr" rid="B45">45</xref>–<xref ref-type="bibr" rid="B47">47</xref>]. This hypothesis was further supported by observations demonstrating that antibiotic therapy not only suppressed clinical disease activity but also reduced the proportion of malignant T cells in skin lesions colonized by enterotoxin-producing <italic><tp:taxon-name><tp:taxon-name-part taxon-name-part-type="genus" reg="Staphylococcus">S.</tp:taxon-name-part> <tp:taxon-name-part taxon-name-part-type="species" reg="aureus">aureus</tp:taxon-name-part></tp:taxon-name></italic> in patients with advanced <abbrev xlink:title="Sézary syndrome">MF</abbrev>/<abbrev xlink:title="Sézary syndrome">SS</abbrev> [<xref ref-type="bibr" rid="B48">48</xref>].</p>
      <p>Additional evidence from mouse models strengthens this concept, showing that animals living in a germ-free environment failed to develop fulminant malignant disease [<xref ref-type="bibr" rid="B49">49</xref>]. In another murine model, topical triple antibiotic treatment significantly delayed tumor onset and growth and prolonged survival [<xref ref-type="bibr" rid="B50">50</xref>].</p>
      <p>Several studies have begun to elucidate the mechanisms by which <italic><tp:taxon-name><tp:taxon-name-part taxon-name-part-type="genus" reg="Staphylococcus">Staphylococcus</tp:taxon-name-part> <tp:taxon-name-part taxon-name-part-type="species" reg="aureus">aureus</tp:taxon-name-part></tp:taxon-name></italic> and its enterotoxins contribute to malignant T-cell expansion in <abbrev xlink:title="Sézary syndrome">MF</abbrev> or <abbrev xlink:title="Sézary syndrome">SS</abbrev>.</p>
      <p>Woetmann et al. showed that non-malignant T cells enhance proliferation of the malignant cells in a staphylococcal enterotoxin- and MHC class II–dependent manner [<xref ref-type="bibr" rid="B51">51</xref>].</p>
      <p>Willerslev-Olsen et al. demonstrated that Staphylococcal enterotoxin A (SEA) activates signal transducer and activator of transcription 3 (STAT3) and induces interleukin-17 expression in malignant T cells when co-cultured with non-malignant T cells [<xref ref-type="bibr" rid="B52">52</xref>]. He further showed that <italic><tp:taxon-name><tp:taxon-name-part taxon-name-part-type="genus" reg="Staphylococcus">Staphylococcus</tp:taxon-name-part> <tp:taxon-name-part taxon-name-part-type="species" reg="aureus">aureus</tp:taxon-name-part></tp:taxon-name></italic> and its enterotoxins enhance the expression of the oncogenic microRNA (miRNA) 155 (miR-155) [<xref ref-type="bibr" rid="B53">53</xref>].</p>
      <p>Zeng et al. demonstrated that upon exposure to patient-derived <italic><tp:taxon-name><tp:taxon-name-part taxon-name-part-type="genus" reg="Staphylococcus">S.</tp:taxon-name-part> <tp:taxon-name-part taxon-name-part-type="species" reg="aureus">aureus</tp:taxon-name-part></tp:taxon-name></italic> and its enterotoxin, keratinocytes stimulate IL-2Rγ/JAK3-dependent proliferation of malignant and nonmalignant T cells in an environment with nonmalignant T cells [<xref ref-type="bibr" rid="B54">54</xref>].</p>
      <p>Gluud et al. demonstrated that SE-producing <italic><tp:taxon-name><tp:taxon-name-part taxon-name-part-type="genus" reg="Staphylococcus">S.</tp:taxon-name-part> <tp:taxon-name-part taxon-name-part-type="species" reg="aureus">aureus</tp:taxon-name-part></tp:taxon-name></italic> promotes skin barrier impairment in <abbrev xlink:title="Cutaneous T-cell lymphomas">CTCL</abbrev> through cytokine-driven, JAK-dependent repression of structural proteins in keratinocytes [<xref ref-type="bibr" rid="B55">55</xref>].</p>
      <p><italic><tp:taxon-name><tp:taxon-name-part taxon-name-part-type="genus" reg="Staphylococcus">Staphylococcus</tp:taxon-name-part> <tp:taxon-name-part taxon-name-part-type="species" reg="aureus">aureus</tp:taxon-name-part></tp:taxon-name></italic> enterotoxins can further induce drug resistance in primary malignant T cells. Using multimodal single-cell sequencing, they identified activation of T-cell receptor (TCR), NF-κB, and JAK/STAT signaling pathways, which have been associated with therapeutic resistance, as potential mediators of enterotoxin-induced drug resistance [<xref ref-type="bibr" rid="B56">56</xref>]. It has been demonstrated that treatment with <abbrev xlink:title="narrow-band ultraviolet B">NB-UVB</abbrev> in <abbrev xlink:title="Sézary syndrome">MF</abbrev> patients is associated with a significant post-treatment reduction of <italic><tp:taxon-name><tp:taxon-name-part taxon-name-part-type="genus" reg="Staphylococcus">Staphylococcus</tp:taxon-name-part> <tp:taxon-name-part taxon-name-part-type="species" reg="aureus">aureus</tp:taxon-name-part></tp:taxon-name></italic> in lesional skin [<xref ref-type="bibr" rid="B57">57</xref>].</p>
      <p>Furthermore, the findings of a murine model suggest that combining phototherapy with targeted antimicrobial strategies could provide twofold benefits: direct tumor cell cytotoxicity and disruption of bacterial-mediated resistance mechanisms [<xref ref-type="bibr" rid="B50">50</xref>].The importance of the skin microbiome is further supported by observations that therapeutic interventions other than antibiotics may also modulate bacterial dysbiosis. Complementing these findings, Chrisman et al. showed that radiation therapy not only eliminates lesions through induction of apoptosis, but also promotes restoration of the skin barrier and recolonization with bacterial taxa associated with a healthy skin microbiome [<xref ref-type="bibr" rid="B58">58</xref>].</p>
      <p>Taken together, the data underscore a central role for <italic><tp:taxon-name><tp:taxon-name-part taxon-name-part-type="genus" reg="Staphylococcus">Staphylococcus</tp:taxon-name-part> <tp:taxon-name-part taxon-name-part-type="species" reg="aureus">aureus</tp:taxon-name-part></tp:taxon-name></italic>–driven immune modulation in <abbrev xlink:title="Sézary syndrome">MF</abbrev> and <abbrev xlink:title="Sézary syndrome">SS</abbrev> pathogenesis and support microbial targeting as an integral component of effective therapeutic strategies.</p>
      <p>Indeed, various clinical studies have indicated that, under certain conditions, treatment with antibiotics ameliorates skin symptoms, particularly in patients with Sézary syndrome or erythrodermic mycosis fungoides [<xref ref-type="bibr" rid="B43">43</xref>, <xref ref-type="bibr" rid="B45">45</xref>, <xref ref-type="bibr" rid="B47">47</xref>, <xref ref-type="bibr" rid="B48">48</xref>, <xref ref-type="bibr" rid="B59">59</xref>].</p>
    </sec>
    <sec sec-type="7.0 Emerging immunomodulatory strategies target inflammatory signaling" id="sec12">
      <title>7.0 Emerging immunomodulatory strategies target inflammatory signaling</title>
      <p>Building on the concept that the pathogenesis of <abbrev xlink:title="Sézary syndrome">MF</abbrev>/<abbrev xlink:title="Sézary syndrome">SS</abbrev> is driven by inflammation, emerging therapies such as Janus kinase (JAK) inhibitors and agents that target the OX40/OX40L pathway aim to disrupt cytokine-driven survival signals and T-cell activation more selectively within the tumor microenvironment. These approaches may complement established therapies.</p>
      <sec sec-type="7.1 OX40/OX40L blockade" id="sec13">
        <title>7.1 OX40/OX40L blockade</title>
        <p>OX40 (CD134) is a costimulatory receptor of the TNF receptor superfamily that is upregulated on activated CD4<sup>+</sup> and CD8<sup>+</sup> T cells. Its ligand, OX40L (CD252), is mainly expressed by antigen-presenting cells, including dendritic cells, B cells, and macrophages. Engagement of OX40 by OX40L enhances T-cell proliferation, survival, and effector functions such as cytokine production [<xref ref-type="bibr" rid="B60">60</xref>–<xref ref-type="bibr" rid="B62">62</xref>]. In <abbrev xlink:title="Sézary syndrome">MF</abbrev>/<abbrev xlink:title="Sézary syndrome">SS</abbrev>, both OX40 and OX40L are expressed in an aberrant manner on both malignant and reactive T cells within the tumor microenvironment. This suggests that this axis may contribute to disease progression by promoting pathogenic T-cell activation. Guglielmo et al. recently reviewed this concept in detail [<xref ref-type="bibr" rid="B63">63</xref>].</p>
        <p>Kawana et al. demonstrated the active involvement of OX40–OX40L axis in the pathophysiology of <abbrev xlink:title="Sézary syndrome">MF</abbrev> and <abbrev xlink:title="Sézary syndrome">SS</abbrev> [<xref ref-type="bibr" rid="B64">64</xref>]. They analyzed the mRNA expression of both molecules and observed markedly higher levels in lesional skin than in the healthy controls. OX40 expression was associated with poorer disease-specific survival. They also observed that <abbrev xlink:title="Cutaneous T-cell lymphomas">CTCL</abbrev> cell lines expressed both molecules on their surface and that proliferation could be reduced by blocking either OX40 or OX40L with neutralizing antibodies. Furthermore, in a xenograft mouse model, treatment with either antibody significantly slowed tumor growth. Taken together, these observations suggest that interfering with OX40–OX40L interactions could provide a new therapeutic strategy for <abbrev xlink:title="Sézary syndrome">MF</abbrev>/<abbrev xlink:title="Sézary syndrome">SS</abbrev>.</p>
        <p>Therapeutically, OX40-targeting strategies are already being explored in inflammatory skin diseases such as atopic dermatitis, where OX40-blocking antibodies—including rocatinlimab [<xref ref-type="bibr" rid="B65">65</xref>] and amlitelimab [<xref ref-type="bibr" rid="B66">66</xref>] have demonstrated reductions in pathogenic T-cell activation and improvements in inflammatory biomarkers in early clinical trials [<xref ref-type="bibr" rid="B63">63</xref>]. These developments highlight the potential relevance of OX40 pathway modulation for <abbrev xlink:title="Sézary syndrome">MF</abbrev>/<abbrev xlink:title="Sézary syndrome">SS</abbrev> and support ongoing interest in evaluating this axis as a future therapeutic target.</p>
      </sec>
      <sec sec-type="7.2 JAK/STAT inhibition" id="sec14">
        <title>7.2 JAK/STAT inhibition</title>
        <p>The JAK/STAT signaling pathway plays a key role in regulating immune responses and inflammation and its dysregulation is a well-recognized feature of cutaneous T-cell lymphomas. Somatic mutations in JAK1, JAK3, STAT3 and STAT5B, as well as copy-number gains affecting JAK2, STAT3 and STAT5B, lead to constitutive activation of downstream proliferative and anti-apoptotic signaling in malignant T cells [<xref ref-type="bibr" rid="B67">67</xref>]. An integrative review of <abbrev xlink:title="Sézary syndrome">MF</abbrev>/<abbrev xlink:title="Sézary syndrome">SS</abbrev> highlights persistent STAT3 and STAT5 activation as key molecular features associated with disease progression and therapeutic response [<xref ref-type="bibr" rid="B68">68</xref>].</p>
        <p>These findings highlight the dependence of malignant T cells on JAK/STAT-mediated survival signaling. This signaling is further amplified by cytokines produced within the tumor microenvironment.</p>
        <p>An analysis of leukemic <abbrev xlink:title="Cutaneous T-cell lymphomas">CTCL</abbrev> showed frequent copy number gains and hyperactivation of STAT3 and STAT5. It has been demonstrated that pharmacological inhibition of upstream kinases, particularly p21-activated kinase (PAK), which promotes STAT3/5 activation, as well as direct targeting of STAT3/5 signaling reduced proliferation and induced apoptosis of malignant T cells. In an intradermal xenograft model, PAK inhibition significantly decreased tumor growth, supporting STAT3/5-dependent signaling as a potential therapeutic target in advanced disease [<xref ref-type="bibr" rid="B69">69</xref>].</p>
        <p>Dey et al. investigated IQDMA, a small-molecule inhibitor targeting the CDC42–PAK2 signaling axis, as a novel targeted agent in <abbrev xlink:title="Cutaneous T-cell lymphomas">CTCL</abbrev> and showed that it disrupts STAT3/5 signaling through collapse of the CDC42–PAK2–STAT nuclear transport axis, thereby suppressing tumor growth [<xref ref-type="bibr" rid="B70">70</xref>].</p>
        <p>Other preclinical studies demonstrate that the JAK1/2 inhibitor ruxolitinib effectively suppresses STAT phosphorylation, reduces proliferation, and induces apoptosis in <abbrev xlink:title="Cutaneous T-cell lymphomas">CTCL</abbrev> cell lines [<xref ref-type="bibr" rid="B71">71</xref>]. These findings provided a basis for clinical testing.</p>
        <p>In a biomarker-driven phase 2 study of ruxolitinib in relapsed/refractory T-cell lymphomas, limited activity was observed in <abbrev xlink:title="Sézary syndrome">MF</abbrev>, with only one response among seven <abbrev xlink:title="Sézary syndrome">MF</abbrev> patients, whereas more durable responses occurred in tumors harboring JAK/STAT pathway mutations or phosphorylated STAT3 [<xref ref-type="bibr" rid="B72">72</xref>].</p>
        <p>A recent systematic review summarizing thirteen published reports on JAK inhibitors in <abbrev xlink:title="Cutaneous T-cell lymphomas">CTCL</abbrev> found response rates ranging from 11–35% in clinical studies, with 14–45% in <abbrev xlink:title="Sézary syndrome">MF</abbrev>. The review also described rare cases of <italic>de novo</italic> or relapsed <abbrev xlink:title="Cutaneous T-cell lymphomas">CTCL</abbrev> occurring in patients receiving JAK inhibitors for autoimmune diseases, indicating that JAK/STAT pathway inhibition may exert both therapeutic and potentially disease-promoting effects depending on the clinical and biological context [<xref ref-type="bibr" rid="B67">67</xref>].</p>
        <p>A recent multicentre real-world study by Amitay-Laish et al. evaluated systemic JAK inhibitor use in 20 patients with <abbrev xlink:title="Sézary syndrome">MF</abbrev>/<abbrev xlink:title="Sézary syndrome">SS</abbrev> across different clinical settings, none of whom had received treatment primarily for lymphoma-directed therapy. The heterogeneous outcomes, including reports of disease progression, highlight the need for careful patient selection and further prospective evaluation of JAK inhibitors in <abbrev xlink:title="Sézary syndrome">MF</abbrev>/<abbrev xlink:title="Sézary syndrome">SS</abbrev> [<xref ref-type="bibr" rid="B73">73</xref>].</p>
        <p>In their narrative review, Packer and Brunner concluded that although JAK inhibitors are established therapies in inflammatory and hematologic diseases, their use in <abbrev xlink:title="Cutaneous T-cell lymphomas">CTCL</abbrev> remains investigational and will require biomarker-guided studies to identify patients whose tumors are truly dependent on JAK/STAT signaling [<xref ref-type="bibr" rid="B74">74</xref>].</p>
      </sec>
      <sec sec-type="7.3 Checkpoint inhibitors" id="sec15">
        <title>7.3 Checkpoint inhibitors</title>
        <p>The increasingly immunosuppressive tumor microenvironment in <abbrev xlink:title="Sézary syndrome">MF</abbrev> during disease progression is characterized by high PD-L1 expression and accumulation of PD-1-expressing exhausted T cells. PD-1 blockade aims to restore T-cell activation and cytotoxic function, thereby enhancing antitumor immune surveillance. However, because PD-1 is also expressed by regulatory T cells and, in some cases, by the malignant T-cell clone itself, checkpoint inhibition may exert complex and potentially opposing effects within the tumor microenvironment, which may contribute to the comparatively lower clinical efficacy observed in <abbrev xlink:title="Cutaneous T-cell lymphomas">CTCL</abbrev> compared with other malignancies [<xref ref-type="bibr" rid="B75">75</xref>].</p>
        <p>A recent systematic review including 66 patients with refractory mycosis fungoides and Sézary syndrome suggests that immune checkpoint inhibitors, particularly pembrolizumab, may provide meaningful clinical benefit in selected patients. Overall, complete and partial responses were observed in 20% and 33% of patients, respectively, while treatment-related discontinuation due to adverse events was uncommon [<xref ref-type="bibr" rid="B76">76</xref>].</p>
      </sec>
    </sec>
    <sec sec-type="8.0 Tumor-directed therapies targeting the malignant clone" id="sec16">
      <title>8.0 Tumor-directed therapies targeting the malignant clone</title>
      <p>In parallel, several approved systemic therapies directly target malignant T cells. Brentuximab vedotin, an anti-CD30 antibody–drug conjugate, induces selective cytotoxicity in CD30-expressing cells and has demonstrated significant clinical efficacy in advanced disease [<xref ref-type="bibr" rid="B77">77</xref>, <xref ref-type="bibr" rid="B78">78</xref>]. Mogamulizumab, a defucosylated anti-CCR4 monoclonal antibody, eliminates malignant CCR4-positive T cells through antibody-dependent cellular cytotoxicity while simultaneously depleting CCR4-expressing regulatory T cells, thereby reshaping the tumor microenvironment and potentially enhancing antitumor immune responses [<xref ref-type="bibr" rid="B79">79</xref>, <xref ref-type="bibr" rid="B80">80</xref>].</p>
      <p>Thus, whereas brentuximab vedotin primarily mediates direct cytotoxicity against the malignant clone, mogamulizumab combines direct antitumor activity with immunomodulatory effects on the tumor microenvironment. An overview of the principal therapeutic targets and mechanisms of action discussed above is provided in Fig. <xref ref-type="fig" rid="F1">1</xref>.</p>
      <fig id="F1">
        <object-id content-type="doi">10.1553/skindeep.2026.200237.figure1</object-id>
        <object-id content-type="arpha">1C849792-FF77-5A45-83E3-ABF6DCCFCF80</object-id>
        <label>Figure 1.</label>
        <caption>
          <p>Overview of therapeutic targets and mechanisms of action affecting malignant cells and the inflammatory microenvironment in <abbrev xlink:title="Sézary syndrome">MF</abbrev>/<abbrev xlink:title="Sézary syndrome">SS</abbrev> (Created in <ext-link xlink:href="https://BioRender.com" ext-link-type="uri">https://BioRender.com</ext-link>).</p>
        </caption>
        <graphic xlink:href="skinonline-02-001_article-200237__-g001.jpg" id="oo_1811301.jpg">
          <uri content-type="original_file">https://binary.pensoft.net/fig/1811301</uri>
        </graphic>
      </fig>
    </sec>
    <sec sec-type="9.0 Conclusion" id="sec17">
      <title>9.0 Conclusion</title>
      <p>The concept of malignant inflammation provides a framework for understanding cutaneous T-cell lymphoma as a disease sustained not only by malignant T cells but also by dynamic interactions with the surrounding immune microenvironment.</p>
      <p>Increasing evidence indicates that cytokines and direct cell-cell interactions contribute to the persistence of malignant T cells and shape disease progression.</p>
      <p>This perspective recognizes the tumor microenvironment as an active determinant of <abbrev xlink:title="Sézary syndrome">MF</abbrev>/<abbrev xlink:title="Sézary syndrome">SS</abbrev> pathogenesis, contributing to malignant T-cell persistence, immune dysregulation, and disease progression.</p>
      <p>While current therapies target either malignant T cells or components of the inflammatory milieu, the extent to which simultaneous modulation of both compartments translates into improved clinical outcomes remains to be determined. Future studies should further define the reciprocal interactions between malignant and benign immune cells, identify biomarkers reflecting microenvironmental activity, and evaluate whether therapeutic strategies addressing both the malignant clone and its supportive microenvironment provide additional clinical benefit.</p>
    </sec>
  </body>
  <back>
    <ref-list>
      <title>References</title>
      <ref id="B1">
        <mixed-citation>1. Jawed SI, Myskowski PL, Horwitz S, Moskowitz A, Querfeld C. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers. J Am Acad Dermatol. 2014;70:205.e1–205.e16. <ext-link xlink:href="10.1016/j.jaad.2013.07.049" ext-link-type="doi">https://doi.org/10.1016/j.jaad.2013.07.049</ext-link></mixed-citation>
      </ref>
      <ref id="B2">
        <mixed-citation>2. Dobos G, Lazaridou I, de Masson A. Mycosis fungoides and Sézary syndrome: microenvironment and cancer progression. Cancers (Basel). 2023;15:746. <ext-link xlink:href="10.3390/cancers15030746" ext-link-type="doi">https://doi.org/10.3390/cancers15030746</ext-link></mixed-citation>
      </ref>
      <ref id="B3">
        <mixed-citation>3. Roediger B, Schlapbach C. T cells in the skin: lymphoma and inflammatory skin disease. J Allergy Clin Immunol. 2022;149:1172–84. <ext-link xlink:href="10.1016/j.jaci.2022.02.015" ext-link-type="doi">https://doi.org/10.1016/j.jaci.2022.02.015</ext-link></mixed-citation>
      </ref>
      <ref id="B4">
        <mixed-citation>4. Stolearenco V, Namini MRJ, Hasselager SS, Gluud M, Buus TB, Willerslev-Olsen A, et al. Cellular interactions and inflammation in the pathogenesis of cutaneous T-cell lymphoma. Front Cell Dev Biol. 2020;8:851. <ext-link xlink:href="10.3389/fcell.2020.00851" ext-link-type="doi">https://doi.org/10.3389/fcell.2020.00851</ext-link></mixed-citation>
      </ref>
      <ref id="B5">
        <mixed-citation>5. Vieyra-Garcia P, Crouch JD, O’Malley JT, Seger EW, Yang CH, Teague JE, et al. Benign T cells drive clinical skin inflammation in cutaneous T cell lymphoma. JCI Insight. 2019;4:e124233. <ext-link xlink:href="10.1172/jci.insight.124233" ext-link-type="doi">https://doi.org/10.1172/jci.insight.124233</ext-link></mixed-citation>
      </ref>
      <ref id="B6">
        <mixed-citation>6. Krejsgaard T, Lindahl LM, Mongan NP, Wasik MA, Litvinov IV, Iversen L, et al. Malignant inflammation in cutaneous T‐cell lymphoma—a hostile takeover. Semin Immunopathol. 2017;39:269–82. <ext-link xlink:href="10.1007/s00281-016-0594-9" ext-link-type="doi">https://doi.org/10.1007/s00281-016-0594-9</ext-link></mixed-citation>
      </ref>
      <ref id="B7">
        <mixed-citation>7. Guenova E, Watanabe R, Teague JE, Desimone JA, Jiang Y, Dowlatshahi M, et al. TH2 cytokines from malignant cells suppress TH1 responses and enforce a global TH2 bias in leukemic cutaneous T-cell lymphoma. Clin Cancer Res. 2013;19:3755–63. <ext-link xlink:href="10.1158/1078-0432.CCR-12-3488" ext-link-type="doi">https://doi.org/10.1158/1078-0432.CCR-12-3488</ext-link></mixed-citation>
      </ref>
      <ref id="B8">
        <mixed-citation>8. Mazzetto R, Miceli P, Tartaglia J, Ciolfi C, Sernicola A, Alaibac M. Role of IL-4 and IL-13 in Cutaneous T Cell Lymphoma. Life (Basel). 2024;14:245. <ext-link xlink:href="10.3390/life14020245" ext-link-type="doi">https://doi.org/10.3390/life14020245</ext-link></mixed-citation>
      </ref>
      <ref id="B9">
        <mixed-citation>9. Vieyra-Garcia PA, Wolf P. A deep dive into UV-based phototherapy: mechanisms of action and emerging molecular targets in inflammation and cancer. Pharmacol Ther. 2021;222:107784. <ext-link xlink:href="10.1016/j.pharmthera.2020.107784" ext-link-type="doi">https://doi.org/10.1016/j.pharmthera.2020.107784</ext-link></mixed-citation>
      </ref>
      <ref id="B10">
        <mixed-citation>10. Tota M, Łyko M, Misiąg P, Łacwik J, Laska J, Biliński K, et al. Skin-directed therapies in mycosis fungoides: an update. Dermatol Ther (Heidelb). 2025;15:2765–801. <ext-link xlink:href="10.1007/s13555-025-01511-1" ext-link-type="doi">https://doi.org/10.1007/s13555-025-01511-1</ext-link></mixed-citation>
      </ref>
      <ref id="B11">
        <mixed-citation>11. Pileri A, Guglielmo A, Grandi V, Violetti SA, Fanoni D, Fava P, et al. The microenvironment’s role in mycosis fungoides and sézary syndrome: from progression to therapeutic implications. Cells. 2021;10:2780. <ext-link xlink:href="10.3390/cells10102780" ext-link-type="doi">https://doi.org/10.3390/cells10102780</ext-link></mixed-citation>
      </ref>
      <ref id="B12">
        <mixed-citation>12. Kwantwi LB, Rosen ST, Querfeld C. The Tumor Microenvironment as a Therapeutic Target in Cutaneous T Cell Lymphoma. Cancers (Basel). 2024;16:3368. <ext-link xlink:href="10.3390/cancers16193368" ext-link-type="doi">https://doi.org/10.3390/cancers16193368</ext-link></mixed-citation>
      </ref>
      <ref id="B13">
        <mixed-citation>13. Latzka J, Assaf C, Bagot M, Cozzio A, Dummer R, Guenova E, et al. EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome – update 2023. Eur J Cancer. 2023;195:113343. <ext-link xlink:href="10.1016/j.ejca.2023.113343" ext-link-type="doi">https://doi.org/10.1016/j.ejca.2023.113343</ext-link></mixed-citation>
      </ref>
      <ref id="B14">
        <mixed-citation>14. Barnes PJ. Anti-inflammatory actions of glucocorticoids: molecular mechanisms. Clin Sci. 1998;94:557–72. <ext-link xlink:href="10.1042/cs0940557" ext-link-type="doi">https://doi.org/10.1042/cs0940557</ext-link></mixed-citation>
      </ref>
      <ref id="B15">
        <mixed-citation>15. Ahluwalia A. Topical glucocorticoids and the skin-mechanisms of action: an update. Mediators Inflamm. 1998;7:183–93. <ext-link xlink:href="10.1080/09629359891126" ext-link-type="doi">https://doi.org/10.1080/09629359891126</ext-link></mixed-citation>
      </ref>
      <ref id="B16">
        <mixed-citation>16. Miller JA, Munro DD. Topical corticosteroids: clinical pharmacology and therapeutic use. Drugs. 1980;19:119–34. <ext-link xlink:href="10.2165/00003495-198019020-00004" ext-link-type="doi">https://doi.org/10.2165/00003495-198019020-00004</ext-link></mixed-citation>
      </ref>
      <ref id="B17">
        <mixed-citation>17. Uva L, Miguel D, Pinheiro C, Antunes J, Cruz D, Ferreira J, et al. Mechanisms of action of topical corticosteroids in psoriasis. Int J Endocrinol. 2012;2012:561018. <ext-link xlink:href="10.1155/2012/561018" ext-link-type="doi">https://doi.org/10.1155/2012/561018</ext-link></mixed-citation>
      </ref>
      <ref id="B18">
        <mixed-citation>18. Zackheim HS. Treatment of patch-stage mycosis fungoides with topical corticosteroids. Dermatol Ther. 2003;16:283–7. <ext-link xlink:href="10.1111/j.1396-0296.2003.01639.x" ext-link-type="doi">https://doi.org/10.1111/j.1396-0296.2003.01639.x</ext-link></mixed-citation>
      </ref>
      <ref id="B19">
        <mixed-citation>19. Zackheim HS, Kashani-Sabet M, Amin S. Topical corticosteroids for mycosis fungoides experience in 79 patients. Arch Dermatol. 1998;134:949–54. <ext-link xlink:href="10.1001/archderm.134.8.949" ext-link-type="doi">https://doi.org/10.1001/archderm.134.8.949</ext-link></mixed-citation>
      </ref>
      <ref id="B20">
        <mixed-citation>20. Kartan S, Shalabi D, O’Donnell M, Alpdogan SO, Sahu J, Shi W, et al. Response to topical corticosteroid monotherapy in mycosis fungoides. J Am Acad Dermatol. 2021;84:615–23. <ext-link xlink:href="10.1016/j.jaad.2020.05.043" ext-link-type="doi">https://doi.org/10.1016/j.jaad.2020.05.043</ext-link></mixed-citation>
      </ref>
      <ref id="B21">
        <mixed-citation>21. Olsen EA, Hodak E, Anderson T, Carter JB, Henderson M, Cooper K, et al. Guidelines for phototherapy of mycosis fungoides and Sézary syndrome: a consensus statement of the United States Cutaneous Lymphoma Consortium. J Am Acad Dermatol. 2016;74:27–58. <ext-link xlink:href="10.1016/j.jaad.2015.09.033" ext-link-type="doi">https://doi.org/10.1016/j.jaad.2015.09.033</ext-link></mixed-citation>
      </ref>
      <ref id="B22">
        <mixed-citation>22. Gilchrest BA, Parrish JA, Tanenbaum L, Haynes HA, Fitzpatrick TB. Oral methoxsalen photochemotherapy of mycosis fungoides. Cancer. 1976;38:683–9. <ext-link xlink:href="10.1002/1097-0142(197608)38:2%3C683::AID-CNCR2820380210%3E3.0.CO;2-V" ext-link-type="doi">https://doi.org/10.1002/1097-0142(197608)38:2%3C683::AID-CNCR2820380210%3E3.0.CO;2-V</ext-link></mixed-citation>
      </ref>
      <ref id="B23">
        <mixed-citation>23. Querfeld C, Rosen ST, Kuzel TM, Kirby KA, Roenigk Jr HH, Prinz BM, et al. Long-term follow-up of patients with early-stage cutaneous T-cell lymphoma who achieved complete remission with psoralen plus UV-A monotherapy. Arch Dermatol. 2005;141:305–11. <ext-link xlink:href="10.1001/archderm.141.3.305" ext-link-type="doi">https://doi.org/10.1001/archderm.141.3.305</ext-link></mixed-citation>
      </ref>
      <ref id="B24">
        <mixed-citation>24. Vieyra-Garcia P, Fink-Puches R, Porkert S, Lang R, Pöchlauer S, Ratzinger G, et al. Evaluation of low-dose, low-frequency oral psoralen-UV-A treatment with or without maintenance on early-stage mycosis fungoides: a randomized clinical trial. JAMA Dermatol. 2019;155:538–47. <ext-link xlink:href="10.1001/jamadermatol.2018.5905" ext-link-type="doi">https://doi.org/10.1001/jamadermatol.2018.5905</ext-link></mixed-citation>
      </ref>
      <ref id="B25">
        <mixed-citation>25. Liszewski W, Naym DG, Biskup E, Gniadecki R. Psoralen with ultraviolet A-induced apoptosis of cutaneous lymphoma cell lines is augmented by type I interferons via the JAK1–STAT1 pathway. Photodermatol Photoimmunol Photomed. 2017;33:164–71. <ext-link xlink:href="10.1111/phpp.12302" ext-link-type="doi">https://doi.org/10.1111/phpp.12302</ext-link></mixed-citation>
      </ref>
      <ref id="B26">
        <mixed-citation>26. Vieyra-Garcia PA, Wei T, Naym DG, Fredholm S, Fink-Puches R, Cerroni L, et al. STAT3/5-dependent IL9 overexpression contributes to neoplastic cell survival in mycosis fungoides. Clin Cancer Res. 2016;22:3328–39. <ext-link xlink:href="10.1158/1078-0432.CCR-15-1784" ext-link-type="doi">https://doi.org/10.1158/1078-0432.CCR-15-1784</ext-link></mixed-citation>
      </ref>
      <ref id="B27">
        <mixed-citation>27. Yu Z, Vieyra-Garcia P, Benezeder T, Crouch JD, Kim IR, O’Malley JT, et al. Phototherapy restores deficient type I IFN production and enhances antitumor responses in mycosis fungoides. J Invest Dermatol. 2023;144:621–32.e1. <ext-link xlink:href="10.1016/j.jid.2023.06.212" ext-link-type="doi">https://doi.org/10.1016/j.jid.2023.06.212</ext-link></mixed-citation>
      </ref>
      <ref id="B28">
        <mixed-citation>28. Elsayad K, Guenova E, Assaf C, Nicolay JP, Trautinger F, Stadler R, et al. Radiotherapy in cutaneous lymphomas: recommendations from the EORTC cutaneous lymphoma tumour group. Eur J Cancer. 2024;212:115064. <ext-link xlink:href="10.1016/j.ejca.2024.115064" ext-link-type="doi">https://doi.org/10.1016/j.ejca.2024.115064</ext-link></mixed-citation>
      </ref>
      <ref id="B29">
        <mixed-citation>29. Tandberg DJ, Craciunescu O, Kelsey CR. Radiation therapy for cutaneous T-cell lymphomas. Dermatol Clin. 2015;33:703–13. <ext-link xlink:href="10.1016/j.det.2015.05.006" ext-link-type="doi">https://doi.org/10.1016/j.det.2015.05.006</ext-link></mixed-citation>
      </ref>
      <ref id="B30">
        <mixed-citation>30. Harding SM, Benci JL, Irianto J, Discher DE, Minn AJ, Greenberg RA. Mitotic progression following DNA damage enables pattern recognition within micronuclei. Nature. 2017;548:466–70. <ext-link xlink:href="10.1038/nature23470" ext-link-type="doi">https://doi.org/10.1038/nature23470</ext-link></mixed-citation>
      </ref>
      <ref id="B31">
        <mixed-citation>31. Vanpouille-Box C, Alard A, Aryankalayil MJ, Sarfraz Y, Diamond JM, Schneider RJ, et al. DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity. Nat Commun. 2017;8:15618. <ext-link xlink:href="10.1038/ncomms15618" ext-link-type="doi">https://doi.org/10.1038/ncomms15618</ext-link></mixed-citation>
      </ref>
      <ref id="B32">
        <mixed-citation>32. Deng L, Liang H, Xu M, Yang X, Burnette B, Arina A, et al. STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors. Immunity. 2014;41:843–52. <ext-link xlink:href="10.1016/j.immuni.2014.10.019" ext-link-type="doi">https://doi.org/10.1016/j.immuni.2014.10.019</ext-link></mixed-citation>
      </ref>
      <ref id="B33">
        <mixed-citation>33. Barsoumian HB, Sezen D, Menon H, Younes AI, Hu Y, He K, et al. High plus low dose radiation strategy in combination with TIGIT and PD1 blockade to promote systemic antitumor responses. Cancers (Basel). 2022;14:221. <ext-link xlink:href="10.3390/cancers14010221" ext-link-type="doi">https://doi.org/10.3390/cancers14010221</ext-link></mixed-citation>
      </ref>
      <ref id="B34">
        <mixed-citation>34. Weiner DM, Durgin JS, Wysocka M, Rook AH. The immunopathogenesis and immunotherapy of cutaneous T cell lymphoma: current and future approaches. J Am Acad Dermatol. 2021;84:597–604. <ext-link xlink:href="10.1016/j.jaad.2020.12.026" ext-link-type="doi">https://doi.org/10.1016/j.jaad.2020.12.026</ext-link> [PubMed <ext-link ext-link-type="pmid" xlink:href="33352268">PMID: 33352268</ext-link>]</mixed-citation>
      </ref>
      <ref id="B35">
        <mixed-citation>35. Furudate S, Fujimura T, Kakizaki A, Hidaka T, Asano M, Aiba S. Tumor-associated M2 macrophages in mycosis fungoides acquire immunomodulatory function by interferon alpha and interferon gamma. J Dermatol Sci. 2016;83:182–9. <ext-link xlink:href="10.1016/j.jdermsci.2016.05.004" ext-link-type="doi">https://doi.org/10.1016/j.jdermsci.2016.05.004</ext-link> [PubMed <ext-link ext-link-type="pmid" xlink:href="27342040">PMID: 27342040</ext-link>]</mixed-citation>
      </ref>
      <ref id="B36">
        <mixed-citation>36. Tanita K, Fujimura T, Sato Y, Lyu C, Kambayashi Y, Ogata D, et al. Bexarotene reduces production of CCL22 from tumor-associated macrophages in cutaneous T-cell lymphoma. Front Oncol. 2019;9:907. <ext-link xlink:href="10.3389/fonc.2019.00907" ext-link-type="doi">https://doi.org/10.3389/fonc.2019.00907</ext-link></mixed-citation>
      </ref>
      <ref id="B37">
        <mixed-citation>37. Haserick JR, Richardson JH, Grant DJ. Remission of lesions in mycosis fungoides following topical application of nitrogen mustard. Cleve Clin J Med. 1983;50:90–5. <ext-link xlink:href="10.3949/ccjm.50.2.91" ext-link-type="doi">https://doi.org/10.3949/ccjm.50.2.91</ext-link></mixed-citation>
      </ref>
      <ref id="B38">
        <mixed-citation>38. Kim YH. Management with topical nitrogen mustard in mycosis fungoides. Dermatol Ther. 2003;16:288–98. <ext-link xlink:href="10.1111/j.1396-0296.2003.01640.x" ext-link-type="doi">https://doi.org/10.1111/j.1396-0296.2003.01640.x</ext-link></mixed-citation>
      </ref>
      <ref id="B39">
        <mixed-citation>39. Wehkamp U, Ardigò M, Papadavid E, Querfeld C, Nikbakht N. Chlormethine gel for patients with mycosis fungoides cutaneous T cell lymphoma: a review of efficacy and safety in clinical trial and real-world settings. Adv Ther. 2022;39:3979–4002. <ext-link xlink:href="10.1007/s12325-022-02219-w" ext-link-type="doi">https://doi.org/10.1007/s12325-022-02219-w</ext-link></mixed-citation>
      </ref>
      <ref id="B40">
        <mixed-citation>40. Querfeld C, Scarisbrick JJ, Assaf C, Guenova E, Bagot M, Ortiz-Romero PL, et al. Post hoc analysis of a randomized, controlled, phase 2 study to assess response rates with chlormethine/mechlorethamine gel in patients with stage IA-IIA mycosis fungoides. Dermatology. 2022;238:347–57. <ext-link xlink:href="10.1159/000516138" ext-link-type="doi">https://doi.org/10.1159/000516138</ext-link></mixed-citation>
      </ref>
      <ref id="B41">
        <mixed-citation>41. Hughes CFM, Khot A, McCormack C, Lade S, Westerman DA, Twigger R, et al. Lack of durable disease control with chemotherapy for mycosis fungoides and Sezary syndrome: a comparative study of systemic therapy. Blood. 2015;125:71–81. <ext-link xlink:href="10.1182/blood-2014-07-588236" ext-link-type="doi">https://doi.org/10.1182/blood-2014-07-588236</ext-link></mixed-citation>
      </ref>
      <ref id="B42">
        <mixed-citation>42. Kaye FJ, Bunn Jr PA, Steinberg SM, StockerJL, Ihde DJ, Fischmann AB, et al. A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. N Engl J Med. 1989;321:1784–90. <ext-link xlink:href="10.1056/NEJM198912283212603" ext-link-type="doi">https://doi.org/10.1056/NEJM198912283212603</ext-link></mixed-citation>
      </ref>
      <ref id="B43">
        <mixed-citation>43. Talpur R, Bassett R, Duvic M. Prevalence and treatment of <italic><tp:taxon-name><tp:taxon-name-part taxon-name-part-type="genus">Staphylococcus</tp:taxon-name-part> <tp:taxon-name-part taxon-name-part-type="species">aureus</tp:taxon-name-part></tp:taxon-name></italic> colonization in patients with mycosis fungoides and Sézary syndrome. Br J Dermatol. 2008;159:105–12. <ext-link xlink:href="10.1111/j.1365-2133.2008.08612.x" ext-link-type="doi">https://doi.org/10.1111/j.1365-2133.2008.08612.x</ext-link></mixed-citation>
      </ref>
      <ref id="B44">
        <mixed-citation>44. Axelrod P, Lorber B, Vonderheid E. Infections complicating mycosis fungoides and Sézary syndrome. JAMA. 1992;267:1354–8. <ext-link xlink:href="10.1001/jama.1992.03480100060031" ext-link-type="doi">https://doi.org/10.1001/jama.1992.03480100060031</ext-link></mixed-citation>
      </ref>
      <ref id="B45">
        <mixed-citation>45. Tokura Y, Yagi H, Ohshima A, Kurokawa S, Wakita H, Yokote R, et al. Cutaneous colonization with staphylococci influences the disease activity of Sézary syndrome: a potential role for bacterial superantigens. Br J Dermatol. 1995;133:6–12. <ext-link xlink:href="10.1111/j.1365-2133.1995.tb02485.x" ext-link-type="doi">https://doi.org/10.1111/j.1365-2133.1995.tb02485.x</ext-link></mixed-citation>
      </ref>
      <ref id="B46">
        <mixed-citation>46. Willerslev-Olsen A, Krejsgaard T, Lindahl LM, Bonefeld CM, Wasik MA, Koralov SB, et al. Bacterial toxins fuel disease progression in cutaneous T-cell lymphoma. Toxins (Basel). 2013;5:1402–21. <ext-link xlink:href="10.3390/toxins5081402" ext-link-type="doi">https://doi.org/10.3390/toxins5081402</ext-link> [PubMed <ext-link ext-link-type="pmid" xlink:href="23949004">PMID: 23949004</ext-link>]</mixed-citation>
      </ref>
      <ref id="B47">
        <mixed-citation>47. Emge DA, Bassett RL, Duvic M, Huen AO. Methicillin-resistant <italic><tp:taxon-name><tp:taxon-name-part taxon-name-part-type="genus">Staphylococcus</tp:taxon-name-part> <tp:taxon-name-part taxon-name-part-type="species">aureus</tp:taxon-name-part></tp:taxon-name></italic> (MRSA) is an important pathogen in erythrodermic cutaneous T-cell lymphoma (CTCL) patients. Arch Dermatol Res. 2020;312:283–8. <ext-link xlink:href="10.1007/s00403-019-02015-7" ext-link-type="doi">https://doi.org/10.1007/s00403-019-02015-7</ext-link></mixed-citation>
      </ref>
      <ref id="B48">
        <mixed-citation>48. Lindahl LM, Willerslev-Olsen A, Gjerdrum LMR, Nielsen PR, Blümel E, Rittig AH, et al. Antibiotics inhibit tumor and disease activity in cutaneous T-cell lymphoma. Blood. 2019;134:1072–83. <ext-link xlink:href="10.1182/blood.2018888107" ext-link-type="doi">https://doi.org/10.1182/blood.2018888107</ext-link> [PubMed]</mixed-citation>
      </ref>
      <ref id="B49">
        <mixed-citation>49. Fanok MH, Sun A, Fogli LK, Narendran V, Eckstein M, Kannan K, et al. Role of dysregulated cytokine signaling and bacterial triggers in the pathogenesis of cutaneous T-cell lymphoma. J Invest Dermatol. 2018;138:1116–25. <ext-link xlink:href="10.1016/j.jid.2017.10.028" ext-link-type="doi">https://doi.org/10.1016/j.jid.2017.10.028</ext-link> [PubMed]</mixed-citation>
      </ref>
      <ref id="B50">
        <mixed-citation>50. Dey S, Vieyra-Garcia PA, Joshi AA, Trajanoski S, Wolf P. Modulation of the skin microbiome in cutaneous T-cell lymphoma delays tumour growth and increases survival in the murine EL4 model. Front Immunol. 2024;15:1255859. <ext-link xlink:href="10.3389/fimmu.2024.1255859" ext-link-type="doi">https://doi.org/10.3389/fimmu.2024.1255859</ext-link></mixed-citation>
      </ref>
      <ref id="B51">
        <mixed-citation>51. Woetmann A, Lovato P, Eriksen KW, Krejsgaard T, Labuda T, Zhang Q, et al. Nonmalignant T cells stimulate growth of T-cell lymphoma cells in the presence of bacterial toxins. Blood. 2007;109:3325–32. <ext-link xlink:href="10.1182/blood-2006-04-017863" ext-link-type="doi">https://doi.org/10.1182/blood-2006-04-017863</ext-link></mixed-citation>
      </ref>
      <ref id="B52">
        <mixed-citation>52. Willerslev-Olsen A, Krejsgaard T, Lindahl LM, Litvinov I V, Fredholm S, Petersen DL, et al. Staphylococcal enterotoxin A (SEA) stimulates STAT3 activation and IL-17 expression in cutaneous T-cell lymphoma. Blood. 2016;127:1287–96. <ext-link xlink:href="10.1182/blood-2015-08-662353" ext-link-type="doi">https://doi.org/10.1182/blood-2015-08-662353</ext-link></mixed-citation>
      </ref>
      <ref id="B53">
        <mixed-citation>53. Willerslev-Olsen A, Gjerdrum LMR, Lindahl LM, Buus TB, Pallesen EMH, Gluud M, et al. <italic><tp:taxon-name><tp:taxon-name-part taxon-name-part-type="genus">Staphylococcus</tp:taxon-name-part> <tp:taxon-name-part taxon-name-part-type="species">aureus</tp:taxon-name-part></tp:taxon-name></italic> induces signal transducer and activator of transcription 5–dependent miR-155 expression in cutaneous T-cell lymphoma. J Invest Dermatol. 2021;141:2449–58. <ext-link xlink:href="10.1016/j.jid.2021.01.038" ext-link-type="doi">https://doi.org/10.1016/j.jid.2021.01.038</ext-link></mixed-citation>
      </ref>
      <ref id="B54">
        <mixed-citation>54. Zeng Z, Vadivel CK, Gluud M, Namini MRJ, Yan L, Ahmad S, et al. Keratinocytes present <italic><tp:taxon-name><tp:taxon-name-part taxon-name-part-type="genus">Staphylococcus</tp:taxon-name-part> <tp:taxon-name-part taxon-name-part-type="species">aureus</tp:taxon-name-part></tp:taxon-name></italic> enterotoxins and promote malignant and nonmalignant T cell proliferation in cutaneous T-cell lymphoma. J Invest Dermatol. 2024;144:2789–804.e10. <ext-link xlink:href="10.1016/j.jid.2024.04.018" ext-link-type="doi">https://doi.org/10.1016/j.jid.2024.04.018</ext-link></mixed-citation>
      </ref>
      <ref id="B55">
        <mixed-citation>55. Gluud M, Pallesen EM, Zeng Z, Namini MRJ, Vadivel CK, Gjerdrum LMR, et al. <italic><tp:taxon-name><tp:taxon-name-part taxon-name-part-type="genus">Staphylococcus</tp:taxon-name-part> <tp:taxon-name-part taxon-name-part-type="species">aureus</tp:taxon-name-part></tp:taxon-name></italic> augments epithelial skin barrier damage through T cell activation in cutaneous T cell lymphoma. Allergy. 2026;81:2435–49. <ext-link xlink:href="10.1111/all.70292" ext-link-type="doi">https://doi.org/10.1111/all.70292</ext-link></mixed-citation>
      </ref>
      <ref id="B56">
        <mixed-citation>56. Vadivel CK, Willerslev-Olsen A, J Namini MR, Zeng Z, Yan L, Danielsen M, et al. <italic><tp:taxon-name><tp:taxon-name-part taxon-name-part-type="genus">Staphylococcus</tp:taxon-name-part> <tp:taxon-name-part taxon-name-part-type="species">aureus</tp:taxon-name-part></tp:taxon-name></italic> induces drug resistance in cancer T cells in Sézary syndrome. Blood. 2024;143:1496–512. <ext-link xlink:href="10.1182/blood.2023021671" ext-link-type="doi">https://doi.org/10.1182/blood.2023021671</ext-link></mixed-citation>
      </ref>
      <ref id="B57">
        <mixed-citation>57. Hooper MJ, Enriquez GL, Veon FL, LeWitt TM, Sweeney D, Green SJ, et al. Narrowband ultraviolet B response in cutaneous T-cell lymphoma is characterized by increased bacterial diversity and reduced <italic><tp:taxon-name><tp:taxon-name-part taxon-name-part-type="genus">Staphylococcus</tp:taxon-name-part> <tp:taxon-name-part taxon-name-part-type="species">aureus</tp:taxon-name-part></tp:taxon-name></italic> and <italic><tp:taxon-name><tp:taxon-name-part taxon-name-part-type="genus">Staphylococcus</tp:taxon-name-part> <tp:taxon-name-part taxon-name-part-type="species">lugdunensis</tp:taxon-name-part></tp:taxon-name></italic>. Front Immunol. 2022;13:1022093. <ext-link xlink:href="10.3389/fimmu.2022.1022093" ext-link-type="doi">https://doi.org/10.3389/fimmu.2022.1022093</ext-link></mixed-citation>
      </ref>
      <ref id="B58">
        <mixed-citation>58. Chrisman LP, Pang Y, Hooper MJ, Rajeev-Kumar G, Nguyen WQ, Green SJ, et al. Ionizing radiation improves skin bacterial dysbiosis in cutaneous T-cell lymphoma. Front Immunol. 2024;15:1520214. <ext-link xlink:href="10.3389/fimmu.2024.1520214" ext-link-type="doi">https://doi.org/10.3389/fimmu.2024.1520214</ext-link></mixed-citation>
      </ref>
      <ref id="B59">
        <mixed-citation>59. Lewis DJ, Holder BB, Duvic M. The “Duvic regimen” for erythrodermic flares secondary to <italic><tp:taxon-name><tp:taxon-name-part taxon-name-part-type="genus">Staphylococcus</tp:taxon-name-part> <tp:taxon-name-part taxon-name-part-type="species">aureus</tp:taxon-name-part></tp:taxon-name></italic> in mycosis fungoides and Sézary syndromeInt J Dermatol. 2018;57:123–4. <ext-link xlink:href="10.1111/ijd.13832" ext-link-type="doi">https://doi.org/10.1111/ijd.13832</ext-link></mixed-citation>
      </ref>
      <ref id="B60">
        <mixed-citation>60. Croft M. Control of immunity by the TNFR-related molecule OX40 (CD134). Annu Rev Immunol. 2010;28:57–78. <ext-link xlink:href="10.1146/annurev-immunol-030409-101243" ext-link-type="doi">https://doi.org/10.1146/annurev-immunol-030409-101243</ext-link></mixed-citation>
      </ref>
      <ref id="B61">
        <mixed-citation>61. Fu Y, Lin Q, Zhang Z, Zhang L. Therapeutic strategies for the costimulatory molecule OX40 in T-cell-mediated immunity. Acta Pharm Sin B. 2020;10:414–33. <ext-link xlink:href="10.1016/j.apsb.2019.08.010" ext-link-type="doi">https://doi.org/10.1016/j.apsb.2019.08.010</ext-link></mixed-citation>
      </ref>
      <ref id="B62">
        <mixed-citation>62. Willoughby J, Griffiths J, Tews I, Cragg MS. OX40: Structure and function – what questions remain? Mol Immunol. 2017;83:13–22. <ext-link xlink:href="10.1016/j.molimm.2017.01.006" ext-link-type="doi">https://doi.org/10.1016/j.molimm.2017.01.006</ext-link></mixed-citation>
      </ref>
      <ref id="B63">
        <mixed-citation>63. Guglielmo A, Borghi A, Zengarini C, Piraccini BM, Corazza M, Pileri A. OX40–OX40L axis in cutaneous T-cell lymphomas: pathogenic, prognostic, and potential therapeutic perspectives. Biomolecules. 2025;15:715. <ext-link xlink:href="10.3390/biom15050715" ext-link-type="doi">https://doi.org/10.3390/biom15050715</ext-link> [PubMed <ext-link ext-link-type="pmid" xlink:href="40427608">PMID: 40427608</ext-link>]</mixed-citation>
      </ref>
      <ref id="B64">
        <mixed-citation>64. Kawana Y, Suga H, Kamijo H, Miyagaki T, Sugaya M, Sato S. Roles of OX40 and OX40 Ligand in Mycosis Fungoides and Sézary Syndrome. Int J Mol Sci. 2021;22:12576. <ext-link xlink:href="10.3390/ijms222212576" ext-link-type="doi">https://doi.org/10.3390/ijms222212576</ext-link></mixed-citation>
      </ref>
      <ref id="B65">
        <mixed-citation>65. Guttman-Yassky E, Kabashima K, Worm M, Luna PC, Hong HCH, Chovatiya R, et al. Efficacy and safety of rocatinlimab for the treatment of moderate-to-severe atopic dermatitis in ROCKET-IGNITE and ROCKET-HORIZON: two global, double-blind, placebo-controlled, randomised phase 3 clinical trials. Lancet. 2026;407:53–66. <ext-link xlink:href="10.1016/S0140-6736(25)01865-3" ext-link-type="doi">https://doi.org/10.1016/S0140-6736(25)01865-3</ext-link></mixed-citation>
      </ref>
      <ref id="B66">
        <mixed-citation>66. Weidinger S, Bieber T, Cork MJ, Reich A, Wilson R, Quaratino S, et al. Safety and efficacy of amlitelimab, a fully human nondepleting, noncytotoxic anti-OX40 ligand monoclonal antibody, in atopic dermatitis: results of a phase IIa randomized placebo-controlled trial. Br J Dermatol. 2023;189:531–9. <ext-link xlink:href="10.1093/bjd/ljad240" ext-link-type="doi">https://doi.org/10.1093/bjd/ljad240</ext-link></mixed-citation>
      </ref>
      <ref id="B67">
        <mixed-citation>67. Vahabi SM, Bahramian S, Esmaeili F, Danaei B, Kalantari Y, Fazeli P, et al. JAK Inhibitors in cutaneous T-cell lymphoma: friend or foe? A systematic review of the published literature. Cancers (Basel). 2024;16:861. <ext-link xlink:href="10.3390/cancers16050861" ext-link-type="doi">https://doi.org/10.3390/cancers16050861</ext-link></mixed-citation>
      </ref>
      <ref id="B68">
        <mixed-citation>68. García-Díaz N, Piris MÁ, Ortiz-Romero PL, Vaqué JP. Mycosis fungoides and Sézary syndrome: an integrative review of the pathophysiology, molecular drivers, and targeted therapy. Cancers (Basel). 2021;13:1931. <ext-link xlink:href="10.3390/cancers13081931" ext-link-type="doi">https://doi.org/10.3390/cancers13081931</ext-link></mixed-citation>
      </ref>
      <ref id="B69">
        <mixed-citation>69. Sorger H, Dey S, Vieyra‐Garcia PA, Pölöske D, Teufelberger AR, de Araujo ED, et al. Blocking STAT3 /5 through direct or upstream kinase targeting in leukemic cutaneous T‐cell lymphoma. EMBO Mol Med. 2022;14:e15200. <ext-link xlink:href="10.15252/emmm.202115200" ext-link-type="doi">https://doi.org/10.15252/emmm.202115200</ext-link></mixed-citation>
      </ref>
      <ref id="B70">
        <mixed-citation>70. Dey S, Sorger H, Schlederer M, Perchthaler I, Metzelder M, Kenner L, et al. IQDMA disrupts STAT5 nuclear transport through CDC42-PAK2 axis collapse in cutaneous T-cell lymphoma. Front Immunol. 2026;17:1674527. <ext-link xlink:href="10.3389/fimmu.2026.1674527" ext-link-type="doi">https://doi.org/10.3389/fimmu.2026.1674527</ext-link></mixed-citation>
      </ref>
      <ref id="B71">
        <mixed-citation>71. Pérez C, González-Rincón J, Onaindia A, Almaráz C, García-Díaz N, Pisonero H, et al. Mutated JAK kinases and deregulated STAT activity are potential therapeutic targets in cutaneous T-cell lymphoma. Haematologica. 2015;100:e450–3. <ext-link xlink:href="10.3324/haematol.2015.132837" ext-link-type="doi">https://doi.org/10.3324/haematol.2015.132837</ext-link></mixed-citation>
      </ref>
      <ref id="B72">
        <mixed-citation>72. Moskowitz AJ, Ghione P, Jacobsen E, Ruan J, Schatz JH, Noor S, et al. A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas. Blood. 2021;138:2828–37. <ext-link xlink:href="10.1182/blood.2021013379" ext-link-type="doi">https://doi.org/10.1182/blood.2021013379</ext-link></mixed-citation>
      </ref>
      <ref id="B73">
        <mixed-citation>73. Amitay-Laish I, Mitsunaga K, Ortiz-Romero PL, de Masson A, Morsia E, Sanches JA, et al. Mycosis fungoides/Sézary syndrome and systemic Janus kinase inhibitors: a real-world retrospective study on behalf of the EORTC CLTG. Br J Dermatol. 2026;194:1178–80. <ext-link xlink:href="10.1093/bjd/ljag089" ext-link-type="doi">https://doi.org/10.1093/bjd/ljag089</ext-link></mixed-citation>
      </ref>
      <ref id="B74">
        <mixed-citation>74. Packer SE, Brunner PM. Janus kinase inhibitors – a role for the treatment of cutaneous T-cell lymphomas? Oncol Rev. 2025;19:1482866. <ext-link xlink:href="10.3389/or.2025.1482866" ext-link-type="doi">https://doi.org/10.3389/or.2025.1482866</ext-link></mixed-citation>
      </ref>
      <ref id="B75">
        <mixed-citation>75. Quaglino P, Fava P, Pileri A, Grandi V, Sanlorenzo M, Panasiti V, et al. Phenotypical markers, molecular mutations, and immune microenvironment as targets for new treatments in patients with mycosis fungoides and/or Sézary syndrome. J Invest Dermatol. 2021;141:484–95. <ext-link xlink:href="10.1016/j.jid.2020.07.026" ext-link-type="doi">https://doi.org/10.1016/j.jid.2020.07.026</ext-link></mixed-citation>
      </ref>
      <ref id="B76">
        <mixed-citation>76. Rijal H, Moustaqim-Barrette A, Martinez Villarreal A, Litvinov I V. Use of immune checkpoint inhibitors in refractory mycosis fungoides and Sézary syndrome: a systematic review. J Cutan Med Surg. 2025;29:179–80. <ext-link xlink:href="10.1177/12034754241290816" ext-link-type="doi">https://doi.org/10.1177/12034754241290816</ext-link></mixed-citation>
      </ref>
      <ref id="B77">
        <mixed-citation>77. Siddiqi T, Thomas SH, Chen R. Role of brentuximab vedotin in the treatment of relapsed or refractory Hodgkin lymphoma. Pharmgenomics Pers Med. 2014;7:79–85. <ext-link xlink:href="10.2147/PGPM.S57700" ext-link-type="doi">https://doi.org/10.2147/PGPM.S57700</ext-link></mixed-citation>
      </ref>
      <ref id="B78">
        <mixed-citation>78. Gravanis I, Tzogani K, Hennik P, Graeff P, Schmitt P, Mueller-Berghaus J, et al. The European Medicines Agency Review of brentuximab vedotin (adcetris) for the treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma or systemic anaplastic large cell lymphoma: summary of the scientific assessment of the Committee for Medicinal Products for Human Use. Oncologist. 2016;21:102–9. <ext-link xlink:href="10.1634/theoncologist.2015-0276" ext-link-type="doi">https://doi.org/10.1634/theoncologist.2015-0276</ext-link></mixed-citation>
      </ref>
      <ref id="B79">
        <mixed-citation>79. Wilcox RA. Mogamulizumab: 2 birds, 1 stone. Blood. 2015;125:1847–8. <ext-link xlink:href="10.1182/blood-2015-02-625251" ext-link-type="doi">https://doi.org/10.1182/blood-2015-02-625251</ext-link></mixed-citation>
      </ref>
      <ref id="B80">
        <mixed-citation>80. Duvic M, Pinter-Brown LC, Foss FM, Sokol L, Jorgensen JL, Challagundla P, et al. Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma. Blood. 2015;125:1883–9. <ext-link xlink:href="10.1182/blood-2014-09-600924" ext-link-type="doi">https://doi.org/10.1182/blood-2014-09-600924</ext-link></mixed-citation>
      </ref>
    </ref-list>
    <sec sec-type="Additional information" id="sec18">
      <title>Additional information</title>
      <sec sec-type="Conflict of interest" id="sec19">
        <title>Conflict of interest</title>
        <p>The authors have declared that no competing interests exist.</p>
      </sec>
      <sec sec-type="Artificial Intelligence (AI) use" id="sec20">
        <title>Artificial Intelligence (AI) use</title>
        <p>The authors accept full responsibility for the content of the manuscript, including the disclosure of any use of AI.</p>
        <p>Regarding the use of AI in the preparation of this manuscript, the authors declare the following: GPT.</p>
        <p><bold>Used for</bold>: Language, style and writing.</p>
        <p>During the preparation of this work the authors used ChatGPT in order to enhance readability and language. After using this tool, the authors reviewed and edited the content as needed and take full responsibility for the content of the publication.</p>
      </sec>
      <sec sec-type="Funding" id="sec21">
        <title>Funding</title>
        <p>No funding was reported.</p>
      </sec>
      <sec sec-type="Author contributions" id="sec22">
        <title>Author contributions</title>
        <p>Conceptualization: RFP, HS. Investigation: HS. Supervision: RFP. Visualization: HS. Writing – original draft: HS. Writing – review and editing: JW, RFP.</p>
      </sec>
      <sec sec-type="Author ORCIDs" id="sec23">
        <title>Author ORCIDs</title>
        <p>H. Schratter <ext-link xlink:href="https://orcid.org/0009-0005-8081-8228" ext-link-type="uri">https://orcid.org/0009-0005-8081-8228</ext-link></p>
        <p>J. Woltsche <ext-link xlink:href="https://orcid.org/0000-0002-2240-6736" ext-link-type="uri">https://orcid.org/0000-0002-2240-6736</ext-link></p>
      </sec>
      <sec sec-type="Data availability" id="sec24">
        <title>Data availability</title>
        <p>All of the data that support the findings of this study are available in the main text.</p>
      </sec>
    </sec>
  </back>
</article>
